Felix Tiongco, MD
Gastroenterology · Chesapeake, VANPI 1124005830
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,863 of the $24,776 with a category attached, or 64.0%. 41 manufacturers reported payments, led by Covidien LP at 35.4% of the total. Reporting peaked in 2019 at $10,854 and has fallen 71.5% since, to $3,093 in 2025. Among gastroenterology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 823 payments — averaging $30.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Covidien LP$9K
- AbbVie$4K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Johnson & Johnson$1K
- QOL Medical, LLC$996
- plus $6K from 35 others
Across 286 payments — averaging $3143.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$326K
- Gilead$168K
- Covidien LP$132K
- Pfizer$98K
- Genentech, Inc.$68K
- Braintree Laboratories, Inc.$37K
- plus $70K from 4 others
What the payments were for
- Consulting fees$8,75335%
- Food & beverage$15,86364%
- Education$1601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,776 in reported general payments places this provider in the 90th percentile of 473 gastroenterology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 15 | $361,938 |
| LinzessLinaclotide | 103 | $87,711 |
| CreonLipase/Protease/Amylase | 12 | $32,920 |
| VemlidyTenofovir Alafenamide | 12 | $15,714 |
| Mesalamine | 13 | $7,977 |
| MovantikNaloxegol Oxalate | 11 | $7,407 |
| Colestipol Hcl | 45 | $5,625 |
| Dexlansoprazole DrDexlansoprazole | 11 | $3,677 |
| Pantoprazole Sodium | 189 | $2,742 |
| Ursodiol | 13 | $2,136 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 119 | $1,898 |
| Sucralfate | 25 | $1,886 |
| Omeprazole | 171 | $1,780 |
| Dicyclomine Hcl | 62 | $1,761 |
| Lubiprostone | 11 | $1,648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa, Vemlidy | $676 | $377,65227 claims |
| AbbVieLinzess, Creon | $4,162 | $120,631115 claims |
| Redhill Biopharma Inc.Movantik | $54 | $7,40711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 473 gastroenterology providers in Virginia.
Other gastroenterology in Chesapeake
- Walid MakdisiChesapeake$15K
- Jeremy DomanskiChesapeake$14K
- Rene RiveraChesapeake$13K
- Larry ClarkLynchburg$1.2M
- Arun SanyalRichmond$855K
- Mitchell ShiffmanNewport News$635K
- Bryan SauerCharlottesville$540K
- Michael RyanNorfolk$335K
- Brian WentworthCharlottesville$276K
- Vanessa ShamiCharlottesville$210K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.